Original Article

This is an unedited manuscript that has been accepted for publication. NPG are providing this early version of the manuscript as a service to our customers. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

Neuroactive Steroids and Affective Symptoms in Women Across the Weight Spectrum

Received:
Revised:
Accepted:
Published online:

Abstract

3α-5α-Tetrahydroprogesterone, a progesterone metabolite also known as allopregnanolone, and 5α-androstane-3α,17β-diol, a testosterone metabolite also known as 3α-androstanediol, are neuroactive steroids and positive GABAA receptor allosteric modulators. Both anorexia nervosa (AN) and obesity are complicated by affective co-morbidities and hypothalamic-pituitary-gonadal dysregulation. However, it is not known whether neuroactive steroid levels are abnormal at the extremes of the weight spectrum. We hypothesized that serum allopregnanolone and 3α-androstanediol levels would be decreased in AN compared to healthy controls (HC) and negatively associated with affective symptoms throughout the weight spectrum, independent of body mass index (BMI). Thirty-six women were 1 : 1 age-matched across three groups: AN, HC, and overweight/obese (OW/OB). AN were amenorrheic; HC and OW/OB were studied in the follicular phase. Fasting serum neuroactive steroids were measured by gas chromatography/mass spectrometry. Mean Hamilton depression and anxiety scores were highest in AN (p<0.0001). Mean serum allopregnanolone was lower in AN and OW/OB than HC (AN 95.3±56.4 vs OW/OB 73.8±31.3 vs HC 199.5±167.8 pg/ml, p=0.01), despite comparable mean serum progesterone. Allopregnanolone, but not progesterone, was negatively associated with depression and anxiety symptom severity, independent of BMI. Serum 3α-androstanediol levels did not differ among groups and were not associated with depression or anxiety scores, despite a significant negative association between free testosterone levels and both anxiety and depression severity. In conclusion, women at both extremes of the weight spectrum have low mean serum allopregnanolone, which is associated with increased depression and anxiety severity, independent of BMI. Neuroactive steroids such as allopregnanolone may be potential therapeutic targets for depression and anxiety in traditionally treatment-resistant groups including AN.

  • Subscribe to Neuropsychopharmacology for full access:

    $481

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

Author information

Affiliations

  1. Neuroendocrine Unit, Massachusetts General Hospital/Harvard Medical School, Boston, MA

    • Laura E Dichtel
    • , Elizabeth A Lawson
    • , Melanie Schorr
    • , Anne Klibanski
    •  & Karen K Miller
  2. Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA

    • Erinne Meenaghan
    •  & Margaret Lederfine Paskal
  3. Eating Disorders Clinical and Research Program, Massachusetts General Hospital/Harvard Medical School, Boston, MA

    • Kamryn T Eddy
  4. The Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL

    • Graziano Pinna
    •  & Marianela Nelson
  5. National Center for PTSD, Department of Veterans Affairs, VA Boston Healthcare System, and Department of Psychiatry, Boston University School of Medicine, Boston, MA

    • Ann M Rasmusson

Authors

  1. Search for Laura E Dichtel in:

  2. Search for Elizabeth A Lawson in:

  3. Search for Melanie Schorr in:

  4. Search for Erinne Meenaghan in:

  5. Search for Margaret Lederfine Paskal in:

  6. Search for Kamryn T Eddy in:

  7. Search for Graziano Pinna in:

  8. Search for Marianela Nelson in:

  9. Search for Ann M Rasmusson in:

  10. Search for Anne Klibanski in:

  11. Search for Karen K Miller in:

Corresponding author

Correspondence to Laura E Dichtel.